Implications of updated WHO Essential Medicines List

The WHO recently published an updated version of its list of essential medicine and diagnostics. The first WHO essential Medicines List, published in 1977, was a needed revolution in healthcare as it helped establish that medicines fulfilling unmet needs are essential yet remain inaccessible to too many. Since then, the list has been updated every […]

Report: Biopharma licensing eclipsed $33 billion in Q2 2019

Earlier this year, we released an in-depth analysis of 2018 biopharma deals activity. Today’s blog examines more recent biopharma partnering activities, focusing on licensing deals in the second quarter of 2019.   Biopharma licensing booms with a 47% increase compared to Q2 2018 Total disclosed biopharma licensing exhibited strong growth in worldwide spend during the […]

Results from PARP Inhibitor Trials Point to Drastic Changes for Ovarian Cancer Management

What ESMO 2019 announcements mean for the future of the ovarian cancer market and patient care PARP inhibitors have shown extremely encouraging data that could help pave the way for an entirely new treatment algorithm in ovarian cancer. These agents have given patients the opportunity for more effective treatments in the frontline and recurrent settings. […]

Malignant Melanoma – Is Cure a Possibility?

5-year survival data from CheckMate-067 trial released at ESMO 2019, highlighting the efficacy of immunotherapy in the treatment of malignant melanoma, regardless of BRAF status In the last decade, immunotherapy has revolutionised the treatment of malignant melanoma. Before 2011, no effective treatment was available for this chemotherapy-resistant cancer, and patients with metastatic disease (stage IV) […]

UnitedHealth Prefers Oncology Biosimilars Over Roche’s Herceptin, Avastin

Effective Oct. 1, 2019, UnitedHealthcare will be adding utilization criteria for Avastin and Herceptin for members under commercial and community health plans. United is adding a requirement that patients use the biosimilars Kanjinti and Mvasi prior to using the original cancer drugs. Mvasi (bevacizumab-awwb) is the first FDA-approved biosimilar to Avastin (bevacizumab) for the treatment of […]

Limited distribution drugs 101

What are limited distribution drugs? “Limited distribution drug” status is generally assigned to specialty medications with complex regimens to manage. These drugs are expensive, accounting for around 45 percent of the pharmacy drug spend per Express Scripts’ 2018 drug trend report, and require special handling, administration, or monitoring. The therapy areas with the highest number […]

Tracing the Treatment Journey Using Real-World Data

Like the pharmaceutical industry as a whole, the market research and business intelligence functions within have experienced a tremendous transformation over the years—and continue to change. With increasing pressure on resources, heightened competition, and growing complexity of the market landscape, market researchers and the teams the support often need to do more with less, deliver […]

States Continue to Explore a Public-Option Plan to Offer Affordable Healthcare

In May 2019, Washington became the first state to pass legislation to create a public option health plan. Other states are following a similar path, but are at different stages of the process. Several other states are planning to expand coverage options, reduce costs, and increase access to affordable healthcare options.   What is a […]

Pharmaceutical innovation in the APAC region

 First-of-its-kind study ranks companies The Asia Pacific (APAC) region, already a strong contributor to global market growth for the pharmaceutical, is poised to make continued gains in the coming years.  To understand what is on the horizon, we undertook an extensive, data-driven analysis of innovation in the region – the first such analysis to focus […]

Regulatory reform in China enhancing clinical trials review and approval

In order to encourage innovation, speed up access to new drugs and meet the needs of patients, an updated investigational new drug (IND) review procedure was created in China and has been in effect for just over a year. The change drew discussion at both the DIA China 2019 meeting in Beijing in May as […]